Aby Mathew Sells Shares of BioLife Solutions on June 18

Aby Mathew, the Executive Vice President and Chief Scientific Officer at BioLife Solutions, Inc. (NasdaqCM: BLFS), sold 564 shares of the company on June 18, 2026. The shares were sold at an average price of $26.04, amounting to a total value of $14,686.56. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in BioLife Solutions

T. Rowe Price Investment Management boosted its holdings in BioLife Solutions by 1,325,522 shares, bringing its total to 6,506,346 shares valued at approximately $124.1 million. BlackRock also increased its position by 190,151 shares, ending with 6,101,765 shares worth about $116.4 million. Meanwhile, Invesco reduced its stake by 1,583,659 shares, now holding 2,348,532 shares valued at $44.8 million. Vanguard Capital Management initiated a new position with 1,917,708 shares, valued at $36.6 million.

BioLife Solutions, Inc. Stock Down 28.4%

Shares of BioLife Solutions, Inc. traded near $26.04 on Tuesday. The company has a market capitalization of approximately $1.27 billion and a forward P/E ratio of 89.8. Its beta is 1.971, indicating higher volatility compared to the market. Over the past year, the stock has ranged from a low of $17.86 to a high of $29.62. The 50-day moving average is $23.28, and the 200-day moving average is $23.98. The company maintains a strong liquidity position with a current ratio of 7.3 and a quick ratio of 5.15.

Insider Buying and Selling at BioLife Solutions, Inc.

On June 18, 2026, several insiders at BioLife Solutions, Inc. sold shares. Alongside Aby Mathew's sale, Chief Marketing Officer Todd Berard sold 470 shares, Chief Financial Officer Troy Wichterman sold 937 shares, Chief Technology Officer Sean Werner sold 420 shares, and President and CEO Roderick de Greef sold 2,775 shares, all at $26.04 per share.

Analysts Set New Price Targets

Analysts have shown interest in BioLife Solutions, with HC Wainwright & Co. maintaining a 'buy' rating and setting a price target of $32.0 on August 8, 2025. The consensus among analysts is a 'buy' recommendation with a mean target price of $32.3, based on 10 analyst opinions.

About BioLife Solutions

BioLife Solutions, Inc., headquartered in Bothell, Washington, develops and markets bioproduction products for the cell and gene therapy industry. The company provides biopreservation media, automated thawing devices, and cloud-connected storage solutions for biologics. Its products are used globally in research and commercial manufacturing. Founded in 1987, BioLife Solutions is led by CEO Roderick de Greef and employs about 155 people.

Bottom Line

Aby Mathew's recent sale of BioLife Solutions shares is part of a series of insider transactions at the company. Investors often track such moves for insights into company sentiment. While the 13F filings give a historical snapshot, they don't necessarily reflect current positions. BioLife Solutions' stock remains a point of interest for institutional investors and analysts alike.